MSGene

MSGene - Gene overview of all published MS-association studies for CLEC16A

Gene:

CLEC16A (Gop-1; KIAA0350; MGC111457)

Protein:

C-type lectin domain family 16, member A

Chromosome:

16 (View: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 X Y MT)

Status:

Updated 25 November 2011

1. Case-Control Studies (by ethnic group)
				MS Cases				Normal Controls
Study	Population	Source	# Polys	# Subjects (% women)	DX	Onset Age (range)	Age (range)	# Subjects (% women)	Age (range)	Result
Caucasian
ANZgene, 2009	Australia, New Zealand, UK, USA (GWAS)	CL,PO	1 (detail)	1618 (72%)	O/M	34.1 (7-67)	-	3413 (-)	-	Positive
Aulchenko, 2008	Netherlands (GWAS)	CL	2 (detail)	45 (-)	O/M	-	-	195 (-)	-	Negative
Baranzini, 2008	USA, Netherlands, Switzerland (GWAS)	CL	4 (detail)	978 (67%)	MD1&2	34 (11-61)	47 (21-69)	883 (66%)	46 (21-69)	Negative
D'Netto, 2009	Canada	CL	1 (detail)	43 (-)	U	-	-	182 (-)	-	Negative
Hoppenbrouwers, 2008	Overlaps with Aulchenko, 2008	CL	1 (detail)	46 (72%)	P	33 + 11 (-)	-	194 (-)	-	n.a.
Hoppenbrouwers, 2009	Overlaps with Aulchenko, 2008	CL	1 (detail)	45 (-)	O/M	-	-	195 (-)	-	n.a.
Hoppenbrouwers, 2009	Netherlands (outbred)	CL	1 (detail)	490 (-)	O/M	-	-	426 (-)	-	Positive
IMSGC, 2007	USA, UK (GWAS)	CL,PO	2 (detail)	931 (75%)	MD1&2	27.8 (10-51)	38.6 (17-59)	2431 (-)	-	Positive
IMSGC, 2007	UK	CL	1 (detail)	928 (73%)	MD1&2	32.6 (13-60)	45.1 (17-79)	1475 (-)	-	Positive
IMSGC, 2007	USA	CL	1 (detail)	1394 (73%)	MD1&2	33.1 (3-69)	45.4 (18-74)	1512 (-)	-	Positive
IMSGC, 2009	Belgium	CL	1 (detail)	398 (-)	MD1&2	-	47 (-)	461 (-)	-	Trend
IMSGC, 2009	Overlaps with Mero, 2010 (Norway)	CL	1 (detail)	644 (-)	MD1&2	32 (-)	46.3 (-)	1023 (-)	-	n.a.
IMSGC, 2009	Sweden	CL	1 (detail)	1014 (-)	MD1&2	31 (-)	45.6 (-)	1173 (-)	-	Positive
IMSGC, 2009	UK	CL	1 (detail)	2370 (-)	MD1&2	-	44.2 (-)	7078 (-)	-	Positive
IMSGC, 2009	USA	CL	1 (detail)	1311 (-)	MD1&2	-	44.3 (-)	561 (-)	-	Negative
IMSGC, 2011	Europe, USA, Australia, New Zealand (WTCCC2-GWAS)	CL,PO	1 (detail)	9722 (-)	U	32.3 (-)	44.8 (-)	17376 (-)	-	Positive
IMSGC, 2011	Netherlands (GeneMSA-GWAS)	CL	1 (detail)	230 (74%)	U	33 (-)	46 (-)	232 (-)	-	Positive
IMSGC, 2011	USA (GeneMSA-GWAS)	CL	1 (detail)	486 (76%)	U	33 (-)	48 (-)	431 (-)	-	Positive
IMSGC, 2011	Switzerland (GeneMSA-GWAS)	CL	1 (detail)	253 (74%)	U	33 (-)	45 (-)	208 (-)	-	Positive
IMSGC, 2011	Australia, New Zealand (ANZ-GWAS)	CL	1 (detail)	1618 (72%)	U	34 (-)	-	1988 (-)	-	Positive
IMSGC, 2011	USA (BWH-GWAS)	CL	1 (detail)	973 (72%)	U	33 (-)	47 (-)	2952 (-)	-	Positive
IMSGC, 2011	UK, USA (IMSGC2007-GWAS)	CL,PO	1 (detail)	795 (76%)	U	28 (-)	41 (-)	1679 (-)	-	Positive
Martinez, 2009	Spain	CL	2 (detail)	435 (60%)	P	-	-	550 (-)	-	Positive
Mero, 2010	Norway (I)	PO	49 (detail)	807 (-)	O/M	-	-	1027 (-)	-	Positive
Mero, 2010	Norway (II)	CL,PO	6 (detail)	1206 (-)	O/M	-	-	2064 (-)	-	Positive
Mero, 2010	Overlaps with IMSGC, 2007 (UK)	CL,PO	6 (detail)	1102 (-)	O/M	-	-	1980 (-)	-	Positive
Nischwitz, 2010	Germany	CL	31 (detail)	603 (65%)	O/M	-	39.1 (16-75)	825 (54%)	50.9 (18-75)	Positive
Perera, 2009	Overlaps with Rubio, 2008	CL	7 (detail)	1146 (-)	O/M	-	-	1309 (-)	-	Positive
Rubio, 2008	Australia	CL	1 (detail)	1146 (75%)	O/M	32 (7-67)	-	1309 (-)	-	Positive
Sanna, 2010	Italy-Sardinia (GWAS)	CL	1 (detail)	882 (-)	MD1	-	-	872 (-)	-	Negative
Zoledziewska, 2008	Italy (Sardinia)	CL	1 (detail)	1088 (68%)	MD1	31.3 + 10 (5-60)	-	712 (-)	-	Positive
African Descent
Johnson, 2009	USA	CL	2 (detail)	918 (79%)	MD1	-	-	656 (71%)	-	Positive
Other/Mixed
Pandit, 2010	India	CL	2 (detail)	197 (48%)	MD1	30 + 5.6 (-)	35.4 + 3.2 (-)	197 (49%)	31.2 + 4.4 (-)	Positive

Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.

2. Family-Based Studies (by ethnic group)
				Affecteds				Unaffecteds
Study	Population	# Polys	# Families	# Subjects (% women)	DX	Onset Age (range)	Age (range)	# Subjects (% women)	Age (range)	Result
Caucasian
D'Netto, 2009	Overlaps with D'Netto, 2009 (CC)	1 (detail)	43	211 (-)	U	-	-	-	-	Positive
Hoppenbrouwers, 2009	Canada	1 (detail)		1318 (-)	O/M	-	-	1507 (-)	-	Positive
IMSGC, 2007	UK	1 (detail)	380	380 (75%)	MD1&2	27.4 (10-53)	37.4 (17-58)	-	-	Positive
IMSGC, 2007	USA	1 (detail)	229	229 (79%)	MD1&2	31.1 (9-51)	39.4 (19-58)	-	-	Positive
IMSGC, 2007	Overlaps with IMSGC, 2007 (UK-GWAS, CC)	1 (detail)	453	453 (75%)	MD1&2	26.5 (10-48)	38.2 (19-59)	-	-	Positive
IMSGC, 2007	Overlaps with IMSGC, 2007 (USA-GWAS, CC)	1 (detail)	478	478 (74%)	MD1&2	29 (11-51)	39 (17-57)	-	-	Positive
IMSGC, 2009	Australia	1 (detail)	356	-	MD1&2	-	-	-	-	Negative
IMSGC, 2009	Belgium	1 (detail)	113	-	MD1&2	-	-	-	-	Negative
IMSGC, 2009	UK	1 (detail)	1143	-	MD1&2	-	-	-	-	Positive
IMSGC, 2009	USA	1 (detail)	757	-	MD1&2	-	-	-	-	Negative
Mero, 2010	UK	6 (detail)	1153	-	O/M	-	-	-	-	Positive
Zoledziewska, 2008	Italy (Sardinia)	1 (detail)	410	410 (70%)	MD1	25.1 + 7.4 (6-50)	-	-	-	Positive

Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.

Source:  Source of case population -> “CL” (clinic-based), “PO” (population-based), or “CO” (community-based).
# Polys:  Number of polymorphisms tested per gene and per sample.
Onset Age and Age:  Mean or median age at onset or examination, respectively.
DX:  Criteria used to determine MS diagnosis -> "P" (Poser criteria, 1983), "MD1" (McDonald criteria, 2001), "MD2" (revised McDonald criteria, 2005), "MD1&2" (McDonald criteria, 2001 and 2005), "O/M" (other/mixed), "U" (Unknown).
Result:  Overall conclusion reached by authors of the original publication (“positive” usually indicates significant (P<0.05) association in at least one of the performed analyses, and “negative” indicates no evidence for significant association, while “trend” indicates results in between).
(-) :  Either no data provided or in case of overlap, data included in original study.

Print this page

Email this page

MSDF RSS

Text size

Share & Bookmark

MSGene Recent Updates

MSGene Top Results